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Abstract
Purpose
To compare the effectiveness of bevacizumab and ranibizumab in the treatment of exuda-
tive age-related macular degeneration (AMD).
Design
Multicentre, randomized, controlled, double-masked clinical trial in 327 patients. The non-
inferiority margin was 4 letters.
Patients
Patients 60 years of age with primary or recurrent sub- or juxtafoveal choroidal neovascu-
larization (CNV) secondary to AMD with a total area of CNV < 12 disc areas and a best cor-
rected visual acuity (BCVA) score between 20 and 78 letters on an EDTRS like chart in the
study eye.
Methods
Monthly intravitreal injections with 1.25 mg bevacizumab or 0.5 mg ranibizumab were given
during one year. Intention to treat with last observation carried forward analysis was performed.
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Main OutcomeMeasures
Primary outcome was the change in BCVA in the study eye from baseline to 12 months.
Results
The mean gain in BCVA was 5.1 (±14.1) letters in the bevacizumab group (n = 161) and 6.4
(±12.2) letters in the ranibizumab group (n = 166) (p = 0.37). The lower limit of the 95% confi-
dence interval of the difference in BCVA gain was 3.72. The response to bevacizumab was
more varied; 24% of patients showed a gain of15 letters, 11% a loss of15 letters and
65% a gain or loss < 15 letters compared to 19%, 5% and 76% respectively for ranibizumab
(p = 0.038). No significant differences in absolute CRT and CRT change (p = 0.13) or in the
presence of subretinal or intraretinal fluid (p = 0.14 and 0.10, respectively) were observed.
However, the presence of any fluid on SD-OCT (subretinal and/or intraretinal) differed sig-
nificantly (p = 0.020), with definite fluid on SD-OCT in 45% of the patients for bevacizumab
versus 31% for ranibizumab. The occurrence of serious adverse events and adverse events
was similar, with 34 SAEs and 256 AEs in the bevacizumab group and 37 SAEs and 299
AEs in the ranibizumab group (p = 0.87 and p = 0.48, respectively).
Conclusions
Bevacizumab was not inferior to ranibizumab. The response to bevacizumab was more var-
ied with higher percentages of both gainers and losers and more frequently observed retinal
fluid on SD-OCT at 12 months when compared to the ranibizumab group.
Trial Registration
Trialregister.nl NTR1704
Introduction
Exudative age-related macular degeneration (exudative AMD) is the main cause of untreatable
blindness in western countries and a major burden for the elderly population [1,2]. Standard
treatment of exudative AMD is with intravitreal injections of vascular endothelial growth fac-
tor (VEGF) antagonists. These treatments maintain vision in up to 90 percent of patients but
do not cure AMD. [3]
The most commonly used VEGF-antagonists are bevacizumab (Avastin1, Genentech/
Hoffmann-La Roche), ranibizumab (Lucentis1, Genentech/Novartis, Inc.) and aflibercept
(Eylea1,, Bayer). The active part of the molecule is similar in bevacizumab and ranibizumab.
However, bevacizumab is the whole anti-VEGF antibody (150 kD), while ranibizumab is an
antibody fragment. Bevacizumab has a longer half-life in the systemic circulation than ranibi-
zumab while ranibizumab is believed to penetrate the retina better and has higher affinity to
VEGF-A than bevacizumab. These differences could have an impact on safety and efficacy of
these drugs [4].
Since 2008, several comparative clinical trials were initiated to compare bevacizumab and
ranibizumab in exudative AMD. Recently three of these reported bevacizumab not to be infe-
rior to ranibizumab in the treatment of AMD [4–6] while one trial concluded bevacizumab to
be neither non-inferior nor inferior to ranibizumab at the two-year endpoint.[7]. The CATT
The BRAMDStudy
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study was a head-to-head comparison of bevacizumab and ranibizumab in 1,208 AMD patients
using both monthly and ‘as needed’ (Pro Re Nata, PRN) treatment regimens (4 groups). With
the non-inferiority limit set at 5 letters, they found distance visual acuity (VA) after 1 year to be
equivalent for the two drugs within each of these treatment regimens. [6] The IVAN study in
610 patients had a similar study design (4 groups), although the criteria and regimen of retreat-
ment in the PRN groups were different from CATT, and the non-inferiority limit was 3.5 let-
ters. When patients treated with bevacizumab (monthly and PRN) were compared with one-
sided testing (p<0.05), to all patients treated with ranibizumab, bevacizumab was neither non-
inferior nor inferior to ranibizumab. Other efficacy and safety outcomes were similar between
groups, such as retinal thickness using time-domain Optical Coherence Tomography (OCT).
[7] The MANTA research group and the GEFAL research group included 317 and 501 patients
respectively. They compared both drugs in PRN treatment regimens (2 groups). [4,5] In the
MANTA trial, again bevacizumab was non-inferior to ranibizumab for VA at all time points
over 1 year. No significant differences were found in decrease of retinal thickness or in number
of adverse events. [4] In the GEFAL study, the difference in mean change in best corrected
visual acuity favored bevacizumab with 1.68 letters (p<0.0001, 95% confidence interval, -1.16
to +4.93). [5]
The BRAMD study is the second study comparing the efficacy and costs of a regimen of
monthly intravitreal injections of bevacizumab and ranibizumab. Patients with new or recur-
rent exudative AMD were treated for one year in a multicenter study in The Netherlands.
Methods
Study Design, Participants and Setting
The BRAMD trial is a triple masked, randomized, clinical non-inferiority trial. All patients
received monthly injections for 12 months. Between January 2009 and December 2011, 327
patients were recruited at 5 academic medical centres in the Netherlands. There was approval
by the institutional ethical review board at each centre. The study adhered to the tenets of the
Declaration of Helsinki. Eligible patients were 60 years of age or older with primary or recur-
rent sub- or juxtafoveal choroidal neovascularization (CNV) secondary to AMD with a total
area of CNV of< 12 disc areas and a best corrected visual acuity (BCVA) score between 20
and 78 letters on an Early Treatment Diabetic Retinopathy Study- (ETDRS) like chart in the
study eye. In- and exclusion criteria are listed in Table 1.
Decisions about eligibility were made based on Fluorescein Angiograms (FA), fundus pho-
tography and Spectral Domain Optical tomography (SD-OCT). Diagnosis and presence of
active CNV due to AMD was confirmed by independent graders at the UK Network of Oph-
thalmic Reading Centers. The study is registered at the Dutch trial register (Nederlands trial
register) (NTR1704).
Interventions
After informed written consent, participants were allocated to one of two study arms: monthly
injections (window, 30 ± 7 days) with 1.25 mg of bevacizumab or with 0.5 mg ranibizumab.
The commercially available formulations of bevacizumab and ranibizumab were used and
both were prepared for injection by aspiration in a Kendall monoject syringe in an aseptic
manufacturing facility to ensure masking for everybody taking part in the study, apart from
the pharmacists. Syringes were only labelled with the patient identification number. Prepared
syringes were kept at 4°Celsius and injections were given not later than 24 hours after prepara-
tion. Participants attended monthly for a protocolized BCVA measurement, SD-OCT (3D and
cross scans) and intravitreal injection with the allocated drug. Besides the identical syringes
The BRAMDStudy
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masking was also ensured by the fact that the ophthalmologists who performed the injections
did not take part in interpretation of any data or patient assessment. The patient was labelled
as a poor-responder and treatment was changed to the other drug, if at any visit after the third
injection there was a drop in BCVA of more than 10 letters compared to baseline and there
was clear evidence of active CNV or leakage by qualitative SD-OCT and/or FA assessment or
at least two of the following signs of leakage on OCT; central retinal thickening>300 micron
(CRT), intraretinal cysts or subretinal fluid any time after the third injection. The choice for
CRT> 300 micron was based on the assumption that this would be more than two standard
deviations above the mean CRT of a healthy retina in all three the devices used (see also
below). FA and a standardized full ophthalmic examination were done at baseline, 4 months
and exit visit.
Outcome Measures
The primary outcome was the change in BCVA in the study eye from baseline to month 12
assessed with ETDRS- like visual acuity charts at an initial distance of four meter. Secondary
outcome measures were: the proportion of patients with a loss of BCVA less than 15 letters
from baseline at 12 months (responders); the proportion of patients with a loss or a gain of
Table 1. In- and exclusion criteria.
Inclusion criteria
Patients 60 years of age or higher.
Patients with primary or recurrent sub-, juxta- or extrafoveal CNV secondary to AMD, including those with
RAP, that may beneﬁt from anti-VEGF treatment in the opinion of the investigator.
Patients with primary or recurrent sub-, juxta- or extrafoveal CNV secondary to AMD, including those with
RAP, that may beneﬁt from anti-VEGF treatment in the opinion of the investigator.
The total area of CNV (including both classic and occult components) encompassed within the lesion must
be more or equal to 30% of the total lesion area.
The total lesion area should be < 12 disc areas.
A best corrected visual acuity (BCVA) score between 78 and 20 letters (approximately 0,63–0,05 Snellen
equivalent) in the study eye.
Exclusion criteria
Ocular treatment with anti-angiogenic drugs in the last 2 months or Triamcinolone in the last 6 months.
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline.
Patients with angioid streaks or precursors of CNV in either eye due to other causes, such as ocular
histoplasmosis, trauma, or pathologic myopia.
Spherical equivalent of refractive error in the study eye demonstrating more than– 8 dioptres of myopia.
Cataract extraction within three months preceding Baseline
IOP >25 mm Hg
Active intraocular inﬂammation in the study eye.
Vitreous haemorrhage obscuring view of the posterior pole in the study eye.
Presence of a retinal pigment epithelial tear involving the macula in the study eye.
Subretinal haemorrhage in the study eye if the size of the haemorrhage is > 70% of the lesion
Subfoveal ﬁbrosis or atrophy in the study eye.
History of hypersensitivity or allergy to ﬂuorescein.
Inability to obtain fundus photographs, ﬂuorescein angiograms or OCT’s of sufﬁcient quality to be analyzed
and graded by the Central Reading Centre.
Systemic disease with a life expectancy shorter than the duration of the study.
Inability to adhere to the protocol with regard to injection and follow-up visits.
Legally incompetent adult
Refusal to give written informed consent
doi:10.1371/journal.pone.0153052.t001
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BCVA less than 15 letters from baseline at 12 months (stabilizers); the proportion of patients
with 15 letters loss or more of BCVA from baseline at 12 months (losers); the proportion of
patients with 15 letters gain or more of BCVA from baseline at 12 months (gainers); the abso-
lute and percentage change in CRT, as measured by SD-OCT at 4 and 12 months as deter-
mined by the Study Reading Centre at the AMC; the proportion of dropouts before the final 12
months assessments; the proportion of switchers after the third injection; the occurrence of
(serious) adverse events during the 12 months of the study and the costs of the two treatments.
The latter will be discussed in the companion paper.
For SD-OCT examinations, either Cirrus OCT, Spectralis OCT or Topcon OCT could be
used. The type of SD-OCT device used differed between sites, but individual patients were
always scanned with the same device during the study. Although the different devices have
different definitions for the inner- and outer border of the retina, absolute differences were
assumed not to differ. Additionally, all volume scans were reviewed by two investigators to
check for proper positioning on the macula as well as consistency of detection of the inner and
outer border of the retina. Where necessary, borders were adjusted manually. Data on injec-
tions with bevacizumab or ranibizumab and data on imaging and other therapeutic procedures
were gathered with case report forms.
Trial coordinators questioned patients at each visit regarding adverse events and the events
were coded by one researcher at the coordinating site using Medical Dictionary for Regulatory
Activities (MeDdra 14.1) system. All serious adverse events were reviewed by the principal
investigator.
Sample size calculation
Differences in the BCVA change scores from baseline were tested statistically for non-inferior-
ity. Starting from a common standard deviation of the change in BCVA score of 14 letters in
both groups, and assuming an improvement from baseline of 9 letters in both the ranibizumab
and bevacizumab groups, a sample size of 306 patients (153 in each group) has an 80% power
of demonstrating non-inferiority by excluding a difference of 4 letters or more, using a one-
sided t-test and a significance level of 0.05.
Randomization and Masking
The randomisation list was created in a 1:1 ratio by the TENALEA Clinical Trial Data Manage-
ment System. The allocation scheme was stratified by centre, by BCVA in the study eye (52
versus53) and by BCVA in the fellow eye (52 versus53) using the (non-deterministic)
minimization method as described by Pocock and Simon [8] in each substratum. The randomi-
zation list was imported into the data management system Oracle Clinical. Upon randomiza-
tion of a patient, an automatized email notification containing the allocation result was sent to
the site's pharmacy keeping the investigator and trial personnel blinded from treatment alloca-
tion. In case a medication switch was requested in Oracle Clinical, an automatized e-mail noti-
fication containing the updated treatment allocation was sent to the site's pharmacy.
Statistical Analysis
Non-inferiority is assumed if the difference between both groups is 4 letters or less using a one-
sided t-test with a significance level of 0.05. Based on the literature available before January
2009, we set the non-inferiority margin at 4 letters. We performed intention-to-treat (ITT)
analysis. When patients did not complete the study, their last available BCVA-score was used
as the BCVA-score at visit 14 (last-observation-carried-forward). Further, to minimize the risk
of false claiming non-inferiority we used the BCVA at the moment of switch for patients who
The BRAMDStudy
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were switched to the other treatment. The mean BCVA-change per treatment group was calcu-
lated. Covariance analysis of the BCVA-change was used with treatment as fixed factor and
baseline BCVA-score as covariate.
To evaluate the influence of carrying forward the last available BCVA-score to visit 14 in
patients without BCVA-score at visit 14, we used a linear mixed-effects regression analysis to
analyze the repeatedly measured BCVA-change from baseline. In this model we used treat-
ment, visit-number and their interaction as fixed-factors and the baseline BCVA-score as
covariate. We used cubic-splines to flexibly model the change of the BCVA over time. No
assumptions concerning the covariance matrix between the repeated BCVA-scores were made.
The 90% confidence interval of the difference between the estimated means of BCVA-change
from baseline at visit 14 in the two treatment groups was calculated.
The absolute and percentage change from baseline in CRT, as measured by SD-OCT, at 4
and 12 months, were analyzed with covariance analysis. The significance level was 0.05 and
last-observation-carried-forward was performed. Only measurements by the Study Reading
Centre Amsterdam were used.
All proportions were compared between treatment groups using the Pearson chi-square sta-
tistic with a significance level of 0.05. These proportions were calculated after last-observation-
carried-forward in patients without BCVA-score at visit 14.
The numbers of adverse events and serious adverse events during the 12 months of the
study were compared between the treatment groups using the Mann-Whitney U test using a
significance level of 0.05.
Results
Patients
Between January 2009 and December 2011 we randomized 332 patients. The consort flow
chart can be seen in Fig 1. Five patients were excluded from the study before the second injec-
tion and were excluded from further analyses because there was no effect measurement. There
were no substantial imbalances in the demographic or ocular characteristics of both treatment
arms at baseline (Table 2).
National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hos-
pital and University College London Institute of Ophthalmology; Reading Centre, Moorfields
Eye Hospital confirmed presence of active CNV due to AMD in all but one patient. There were
a few other protocol violations: injection other than the masked study medication was adminis-
tered during 7 visits, with a probability of 0.5 of having injected the wrong substance. Other
protocol violations were missed visits due to AEs or SAEs (n = 22), visits where no injection
was given for patient’s safety reasons (n = 5), and inability to obtain SD-OCT or FA.
Visual Acuity
All patients receiving more than one injection were included in the BCVA analysis. At 1 year,
mean gain in BCVA was 5.1 (SD = 14.1) letters in the bevacizumab group and 6.4 (SD = 12.2)
letters in the ranibizumab group (p = 0.37). The lower limit of the 95% confidence interval of
the difference in BCVA gain between the two groups was 3.72. Because this is smaller than 4
letters, we can conclude that bevacizumab is not inferior to ranibizumab (Fig 2).
Secondary outcomes
The response to bevacizumab was significantly more varied than to ranibizumab as in the beva-
cizumab group 24% of patients had a gain of15 letters, 11% a loss of15 letters and 65% a
The BRAMDStudy
PLOS ONE | DOI:10.1371/journal.pone.0153052 May 20, 2016 6 / 16
gain or loss< 15 letters whereas in the ranibizumab group this was 19%, 5% and 76%, respec-
tively (p = 0.038).
The proportions of patients with a BCVA 20/40 remained similar between groups
throughout the whole study: 27% at baseline (43 of 161 patients) in the bevacizumab group ver-
sus 29% (48 of 166) in the ranibizumab group. At exit these proportions increased to 56% (90
out of 161) and 54% (89 out of 166), respectively (p = 0.68).
On SD-OCT, no significant differences in CRT at 12 months were found, with a CRT for
bevacizumab of 258 (SD = 78) micron and for ranibizumab of 246 (SD = 62) micron (p = 0.13).
The change in CRT at exit also did not differ between both drugs, with a mean decrease of 131
(SD = 129) micron in the bevacizumab group and 138 (SD = 117) micron in the ranibizumab
group, (p = 0.31). Fig 3. There were no significant differences in mean change in CRT when
comparing the devices. Mean change in CRT was a decrease of 128 micron (SD = 115) for the
Cirrus, 134 (SD = 115) for the Topcon and 124 micron (SD = 107) for the Spectralis OCT
(p = 0.89).
There were no statistically significant differences at exit in the presence of subretinal or
intraretinal fluid, as judged by local investigators, when evaluated separately (p = 0.14 and
0.10 respectively). However, for the parameter ´any fluid (subretinal and/or intraretinal) on
Fig 1. Consort flow chart.
doi:10.1371/journal.pone.0153052.g001
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SD-OCT´ there was a significant difference (p = 0.020), with definite fluid on SD-OCT in 45%
of the patients at exit in the bevacizumab group versus 31% in the ranibizumab group, and
questionable fluid in 11% in the bevacizumab group versus 10% in the ranibizumab.
As a rescue treatment, patients showing insufficient response to treatment were switched
from the originally assigned treatment to the other based on strictly predefined criteria. Nine
patients originally treated with bevacizumab were switched to ranibizumab. The opposite
switch was done in eight patients. Further analysis of these patients showed that not all criteria
Table 2. Baseline Characteristics.
Characteristic Bevacizumab (n = 161) Ranibizumab (n = 166) all (n = 327)
Age (yr): mean (SD) 79 (7) 78 (7) 78 (7)
Gender–male: n (%) 72 (45%) 73 (44%) 145 (44%)
Caucasian: n(%) 158 (98%) 163 (98%) 321 (98%)
Non caucasian: n (%) 3 (2%) 3 (2%) 6 (2%)
Mean Best Corrected Visual Acuity: mean (SD) 60 (13) 60 (14) 60 (13)
BCVA  52 letters: n (%) 42 (26%) 43 (26%) 85 (26%)
BCVA  53 letters: n (%) 119 (74%) 123 (72%) 242 (74%)
Central retinal thickness (micron): mean (SD) 383 (119) 374 (113) 378 (115)
Tonometry 14.89 (2.97) 15.05 (3.10) 14.98 (3.03)
No Foveal center involvement: n (%), 75 (47%) 77 (46%) 152 (47%)
Active CNV: n (%) 161 (100%) 165 (99.9%) 326 (99.9%)
PED: n (%) 59 (43%) 61 (42%) 120 (42%)
Lesion area* (disc areas): mean (SD) 2.77 (2.16) 2.67 (2.12) 2.72 (2.13)
Lesion area* (disc areas): median (min-max) 2 (0–11) 2 (0–11) 2 (0–11)
Predominantly Classic CNV *: n (%) 44 (28%) 41 (26%) 85 (27%)
Minimally Classic CNV *: n (%) 18 (12%) 33 (21%) 51 (16%)
Occult CNV *: n (%) 93 (60%) 84 (53%) 177 (57%)
Subretinal ﬂuid*: absent n (%) 19 (12%) 12 (7%) 31 (10%)
Subretinal ﬂuid*: deﬁnite n (%) 132 (83%) 141 (86%) 273 (84%)
Subretinal ﬂuid*: questionable n (%) 9 (6%) 10 (6%) 19 (6%)
Subretinal ﬂuid*: Can’t grade n (%) - 1 (1%) 1 (1%)
Intraretinal cysts*: absent n (%) 54 (34%) 51 (31%) 105 (32%)
Intraretinal cysts*: deﬁnite n (%) 88 (53%) 90 (55%) 175 (54%)
Intraretinal cysts*: questionable n (%) 21 (13%) 23 (14%) 44 (14%)
subretinal ﬂuid or intraretinal cysts: absent n (%) - 3 (2%) 3 (1%)
subretinal ﬂuid or intraretinal cysts: deﬁnite: n (%) 154 (96%) 158 (96%) 312 (96%)
subretinal ﬂuid or intraretinal cysts: questionable: n (%) 6 (4%) 3 (2%) 9 (3%)
History of myocardial infarction: n (%) 17 (11%) 18 (11%) 35 (11%)
History of stroke: n (%) 2 (1%) 5 (3%) 7 (2%)
History of transient ischemic attack: n (%) 13 (8%) 16 (10%) 29 (9%)
History of angina pectoris: n (%) 21 (13%) 22 (13%) 43 (13%)
History of dyspnea: n (%) 25 (15%) 24 (14%) 49 (15%)
History of Thrombosis: n (%) 6 (4%) 5 (3%) 11 (3%)
Systolic Blood pressure (mmHg): mean (SD) 150 (23) 155 (22) 152 (23)
Diastolic Blood pressure (mmHg): mean (SD) 80 (11) 82 (11) 81 (11)
EQ-5D state score: mean (SD) 6.2 (1.2) 6.4 (1.3) 6.3 (1.3)
Pseudophakia: n (%) 64 (40%) 68 (41%) 132 (40%)
* = as judged by the local investigator
doi:10.1371/journal.pone.0153052.t002
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for switch were met in 8 out of these 17 patients. Analysis excluding all switchers shows a mean
change in BCVA of 6.64 (SD = 12.8) in the bevacizumab group and 7.11 (SD = 11.6) letters in
the ranibizumab group (p = 0.77).
Thirty-four patients dropped out in the bevacizumab group (21%) compared to 29 (17%) in
the ranibizumab group. Not considering the switchers as drop outs would reduce these num-
bers to 25 (16%) and 21 (13%) respectively (p = 0.53%).
Excluding all dropouts, hence performing a per protocol analysis, results to mean changes
in BCVA of 7.28 (SD = 10.5, n = 127) and 6.47 (SD = 10.77, n = 137) (p = 0.50), resulting in a
small advantage for bevacizumab.
Our study population differed from the other clinical trials since not all patients included in
the study were treatment naive. Forty-three patients had received previous treatment for their
exudative AMD. Nineteen were randomized in the bevacizumab group (12%) and 24 in the
ranibizumab group (15%) (p = 0.51). Of these 43 patients 4 were switched; 3 from ranibizumab
to bevacizumab and one from bevacizumab to ranibizumab. Hence 9% of patients previously
treated were switchers compared to 5% of the treatment naïve patients (p = 0.26).
Patients with a history of treatment had a higher mean BCVA at baseline (61.67, SD = 13.18)
compared to the treatment naïve patients (59.39, SD = 13.37) (p = 0.30). Mean gain in BCVA
for previously treated patients was 1.21 (SD = 12.30) compared to 6.44 (SD = 13.15) for the
treatment naïve patients(p = 0.015).
The mean change in BCVA in previously treated patients differed 1.44 (SE1.44) in favour of
ranibizumab, but the limit of the confidence interval is -3.83, i.e. smaller than 4 letters (p = 0.32).
Fig 2. Mean change in BCVA from baseline.Mean change in BCVA per group. A mixed linear model was used for this graph. This type of
analysis shows a mean gain of 5.9 letters in the bevacizumab group and a mean gain of 6.7 letters in the ranibizumab group (p = 0.56).
doi:10.1371/journal.pone.0153052.g002
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There is no significant interaction between previous treatment and either treatment arm
(p = 0.22).
Treatment naïve patients had a mean change in BCVA of 6.06 (SD = 13.67) letters in the
bevacizumab group and 6.82 letters (SD = 12.63) in the ranibizumab group (p = 0.63). In previ-
ously treated patients mean change in BCVA decreases 2.11 letters (SD = 15.38) and increases
3.83 letters(SD = 8.66) respectively (p = 0.13). (Table 3)
The number of serious adverse events was similar in both groups; 34 SAEs in the bevacizu-
mab group compared to 37 in the ranibizumab group (p = 0.87). Occurrence of non-serious
adverse events was also not statistically significant between groups; 256 AEs for the bevacizu-
mab group versus 299 in the ranibizumab group (p = 0.48). Tables 4 and 5.
There were no statistically significant difference regarding serious adverse events. However,
the study was underpowered to properly analyze safety.
The numbers of SAEs reported here seem higher than mentioned above this is because
some SAEs are related to several groups.
Discussion
Like the CATT trial [6], the BRAMD study demonstrates that the efficacy of monthly treat-
ment of exudative age-related macular degeneration with intravitreal injections of bevacizumab
Fig 3. Mean change in central retinal thickness. Effect of bevacizumab (n = 161, blue) versus ranbizumab (n = 166, red) on the change
of retinal thickness over time. Data are presented as mean ±95%CI. A mixed linear model was used for this graph.
doi:10.1371/journal.pone.0153052.g003
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Table 3. OutcomeMeasures at 12 months.
Bevacizumab (n = 161) Ranibizumab (n = 166) P—value
Best Corrected visual acuity, letters: mean (SD) 65.0 (19.0) 66.4 (15.8) 0.37
Mean gain in BCVA (SD) 5.09 (14.09) 6.40 (12.17) 0.37
Gainers vs losers vs staibilizers 0.038
Gainers (= % with gain  15 letters) 39 (24%) 32 (19%)
Losers (= % with loss  15 letters) 18 (11%) 8 (5%)
Stabilizers (= % with loss or gain < 15 letters) 104 (65%) 126 (76%)
Responders (= % with loss < 15 letters) 143 (89%) 158 (95%) 0.041
Central retinal thickness (CRT) 258 (78) 246 (62) 0.13
Absolute change in CRT: mean (SD) -131 (129) -138 (117) 0.31
% change in CRT: mean (SD) -30 (23) -32 (19) 0.13
Tonometry: mean (SD) 14.01 (3.18) 15.05 (3.05) 0.001
Absolute change in tonometry: mean (SD) -0.93 (2.97) -0.06 (2.67) 0.001
Subretinal ﬂuid* absent vs deﬁnite, vs questionable 0.14
Subretinal ﬂuid*: absent n (%) 101 (63%) 121 (73%)
Subretinal ﬂuid*: deﬁnite n (%) 45 (28%) 35 (21%)
Subretinal ﬂuid*: questionable n (%) 15 (9%) 6%)
intraretinal cysts* absent vs deﬁnite, vs questionable 0.10
Intraretinal cysts*: absent n (%) 104 (65%) 117 (71%)
Intraretinal cysts*: deﬁnite n (%) 40 (25%) 26 (16%)
Intraretinal cysts*: questionable n (%) 17 (11%) 23 (14%)
subretinal ﬂuid or intraretinal cysts absent vs deﬁnite, vs questionable 0.020
subretinal ﬂuid or intraretinal cysts absent: n (%) 71 (44%) 98 (59%)
subretinal ﬂuid or intraretinal cysts: deﬁnite n (%) 72 (45%) 51 (31%)
subretinal ﬂuid or intraretinal cysts: questionable n (%) 18 (11%) 17 (10%)
Active CNV* 58 (36%) 56 (34%) 0.73
Type of lesion* predominantly classic vs minimally classic vs occult 0.035
Predominantly Classic CNV* 38 (24%) 40 (24%)
Minimally classic CNV* 17 (11%) 34 (21%)
Occult CNV* 106 (66%) 92 (55%)
Blood pressure Systolic: mean (SD) 148 (22) 151 (22) 0.71
Diastolic pressure Systolic: mean (SD) 79 (11) 81 (11) 0.48
Number of switchers 9 (6%) 8 (5%) 0.81
* As judged by local investigator
doi:10.1371/journal.pone.0153052.t003
Table 4. Serious adverse events.
Occurrence of SAEs 34 37 0.87
Death due to SAE 1 1
Life-threatening condition 1 2
hospitalisation 30 32
severe or permanent damage 1 0
no relation to study medication 32 35
improbable relation to study medication 1 1
Occurrence of AEs 256 299 0.48
doi:10.1371/journal.pone.0153052.t004
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is not inferior to monthly treatment with ranibizumab. Although the design and outcome of
the BRAMD study were similar to those from the CATT and IVAN trials in general terms,
they differed in detail [6,7]. The BRAMD study is the first fully masked trial comparing bevaci-
zumab and ranibizumab in exudative AMD, as injecting physicians were masked to the medi-
cation administrated.
In addition, in contrast to the CATT and IVAN studies, the BRAMD study also included
patients with recurrent CNV. This seems to contribute to the slightly lower gain in visual acuity
observed in both treatment arms of the BRAMD study.
Consistent with the results of CATT, IVAN and MANTA studies, the mean treatment out-
come with bevacizumab showed slightly less gain in BCVA, but of a magnitude that can be
regarded as clinically insignificant [4,6,7]. However, in the BRAMD study, the response to bev-
acizumab was markedly more varied than the response to ranibizumab, as shown by the distri-
bution of ´stabilizers´, ´gainers´ and ´losers´ in both groups. The proportions of gainers ( 15
letters gain) and losers (15 letters loss) were higher in the bevacizumab group at 24% and
11% versus 19% and 5% in the ranibizumab group, respectively. The larger spread in response
can also be deduced from the larger standard deviation of change in visual acuity of this group
(14 vs. 12). These results suggest that, although the overall mean outcome of bevacizumab and
ranibizumab do not differ, the response to bevacizumab is more varied than to ranibizumab.
This is clinically significant, as twice as many patients experienced substantial vision loss in the
bevacizumab arm of the BRAMD trial as in the ranibizumab group. The percentage of patients
with substantial vision loss in the ranibizumab group was consistent with previous results of
the ANCHOR and MARINA trials, where 95% responded. In the bevacizumab group of the
BRAMD study however, we identified only 89% responders. [9,10]
The IVAN study has not reported the distribution of gainers and losers, but in the CATT
trial 31.3% gainers, 62.7% stabilizers and 6% losers in the bevacizumab monthly group versus
34.2%, 60.2% stabilizers and 5.6% in the ranibizumab monthly group were observed [6]. They
had 62.7% stabilizers in the bevacizumab monthly group versus 60.2% in the ranibizumab
monthly group. These results are not consistent with the BRAMD study outcomes, but the dif-
ferent outcomes between our study and CATT could be due to several differences in the study
design. The CATT protocol of BCVAmeasurements entailed e-EDTRS charts where computer
screens were used and the protocol was semi-automated whereas we used refraction with analog
charts by technicians. CATT included patients with a baseline BCVA between 23 and 82 letters
whereas in the BRAMD this was 20 and 78 letters. Minimum time between injections in CATT
protocol was 21 days whereas in our protocol treatment window was from 23 to 37 days. In
addition, we included patients with new or recurrent disease and 43 of our patients had been
treated previously whereas in CATT this was an exclusion criterion. More importantly, the
Table 5. Adverse events by organ system.
MedDRA system organ class Bevacizumab (n = 49) percentage Ranibizumab (n = 52) percentage
Cardiac disorder 4 2,5 6 3,6
Infection 4 2,5 4 2,4
Nervous system disorder 3 1,9 1 0,6
Injury or procedural complication 5 3,1 1 0,6
Benign or malignant neoplasm 2 1,2 3 1,8
Surgical or medical procedure 13 8,1 16 9,6
Gastrointestinal disorder 2 1,2 2 1,2
Any other system organ class 18 11,2 17 10,2
doi:10.1371/journal.pone.0153052.t005
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CATT protocol allowed the treating physician to refrain from further injections for patients
thought to unlikely benefit from further injections, whereas in our protocol patients with poor
outcome were switched to the other drug.
Like in the CATT study, we observed that presence of any fluid on OCT after 12 monthly
injections is more prevalent in the bevacizumab treated patients (41%) than in the ranibizumab
treated patients (30%). However, this is not reflected in different visual acuity outcomes. Up till
now there is no explanation for this observation and more research is warranted.
That a possible more effective inhibition of leakage by ranibizumab is not always accompa-
nied by a better visual acuity result could be due to the induction of progression of atrophy.
This latter possibility is supported by recent analyses of the CATT and IVAN studies which
indicated more rapid progression of atrophy in patients on monthly treatment than on PRN
treatment.
Our study was designed specifically to compare the effects of maximal treatment of both
VEGF- antagonists. Other studies ([3–6]) included also PRN treatment regimens which are
often used in clinical practice. At present the two most commonly used variable treatment regi-
ments are PRN, with monthly examinations, and a “treat and extend” strategy, where not only
the number of injections but also the number of visits is reduced by extending the interval
between visits based on clinical response[11]. Retreatment is often based on the presence of
fluid on OCT rather than thickness values and the observation of more frequent fluid on OCT
could hence have an influence on the number of injections when using PRN, leading to more
injections for PRN treatment with bevacizumab. Retreatment criteria in these studies were
based on a presence of fluid on OCT, haemorrhage, decrease in VA and presence of leakage on
FA. In CATT slightly more injections were reported with bevacizumab (7.7 ±3.5) compared to
ranibizumab (6.9 ± 3.0) and this was statistically significant. [6]. For IVAN these data are not
published at the moment but the lowest count of ranibizumab injections reported is 6 com-
pared to 7 for bevacizumab [3]. In MANTA there was no significant difference (p = 0.26)
with slightly less injections in the ranibizumab group (5.8 ± 2.7) compared to bevacizumab
(6.1 ± 2.8). [4]. In GEFAL, patients treated with bevacizumab received 6.8 (SD = 2.7)) injec-
tions compared to 6.5 (SD = 2.4) for patients treated with ranibizumab (p = 0.39).[5]
Bevacizumab and other anti-VEGF agents have serious side effects when used systemically
for non-ocular indications, in particular in patients with an increased risk of stroke or other
arterial thrombo-embolic events. [12] Bevacizumab and ranibizumab differ substantially in
pharmacokinetics such as systemic half-life. It is possible therefore that they also differ in sys-
temic side effects in ocular use. [13–15] However, to this day, no convincing differences in sys-
temic adverse events have been shown. The BRAMD study did not have the statistical power to
detect small but clinically meaningful differences in systemic safety. In future studies, our safety
data will be pooled with the results of the other international trials comparing bevacizumab
and ranibizumab for this purpose.
Limitations
The follow-up time of patients in the BRAMD study is restricted to 12 months. We recognize
that patients with AMD are often treated for years. It is highly conceivable however that results
achieved during the first year of monthly treatment are predictive of future results. One year
of intensive treatment should be sufficient to assess whether a patient will or will not continue
to respond. Further, one year of treatment seemed sufficient to our public national funding
agency as well to assess the non-inferiority of bevacizumab against ranibizumab.
In the IVAN trial, increased atrophy was observed in patients treated monthly with ranibi-
zumab for 2 years, [7,15] The IVAN study group also reviewed this in the CATT 2 years results
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and confirmed their own observation. [16,17] This suggests that a trial with monthly injections
might be safer if only conducted for one year.
The number of patients and the length of follow-up are not adequate to provide a full safety
report on bevacizumab versus ranibizumab. Now that our study confirms the non-inferiority
by visual acuity of bevacizumab against ranibizumab and market access of bevacizumab and
ranibizumab in the Netherlands have been redefined as a result of it, we need further post-mar-
keting surveillance to keep track of the safety in the long run.
We further recognize that we evaluated the efficacy of both drugs in a typically clinical trial
setting, i.e. monthly injections while in every day practice most patients are treated on an as
needed basis and we explicitly withhold ourselves from making statements about such treat-
ment schedules.
What might be considered an inconsistency in our protocol is the definition of treatment
failure on the one hand and the indication for becoming a switcher on the other hand. Patients
are considered failures or losers to therapy once they lose 15 letters or more over the year.
However, already when they were still ‘stabilizers’ with a loss of between 10 to 15 letters exclu-
sive, a cross-over to the alternative drug was indicated. We applied an ad-hoc analysis to show
the percentages of patients losing or gaining more than 10 rather than 15 letters with the latter
reported in the results section of this paper. There were 57 patients gaining 10 letters or more
in the bevacizumab group (35%) versus 61 (37%) in the ranibizumab group. For the losers this
was 20 (12%) and 13 (8%) respectively (p = 0.41). This is consistent with the results above
showing more losers in the bevacizumab group.
Three different SD-OCT systems were used. This could lead to some differences. In the
MANTA conversion algorithms were used to deal with this problem. However we believe this
is unnecessary as we analyzed the absolute differences between baseline and exit measure-
ments, and as de Kinkelder et al. found a maximum difference in mean thickness between
brands to be 7.7 micron (Topcon, Spectralis, Cirrus and RTVue) which is an insignificant dif-
ference [18].
Finally, we applied the last observation carried forward at the time of switching to the
alternative drug. usually, this is not done in a intention-to-treat analysis, because the gain in
vision after the switch is not accounted for. However, we did not want to run the risk of dem-
onstrating non-inferiority of bevacizumab to ranibizumab because of patients switching
therapies.
Conclusion
The BRAMD study confirms that bevacizumab is non-inferior to ranibizumab in the treatment
of exudative AMD. Our study did not result in new safety signals, but definitive results should
come from safety data pooled over studies. Being much cheaper it is reasonable to suggest
bevacizumab as the first choice of treatment in exudative AMD. However, in our study more
patients obtained suboptimal results (more than 15 letters loss) in the bevacizumab than in the
ranibizumab group. Therefore, for patients with an initial poor response to bevacizumab, rani-
bizumab may be useful as a second line treatment option.
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